Company Overview
Snapshot
Founded in January 2009 by Ofer Nussbaum, AptaTeck Bio operates with 1–10 employees. The company is currently in a Pre-Funding stage, focusing on immuno-diagnostic assays. A key development for the company was the presentation of its universal probe for signal amplification in immuno-diagnostic assays at the Isranalytica 2017 conference.
Business overview
AptaTeck Bio develops proprietary technology for highly sensitive immuno-assays, utilizing an amplification probe compatible with both antibodies and aptamers. The company's signal amplification technology aims to produce specific, accurate, and reproducible immune diagnostics. It is designed for integration into existing commercial platforms, demonstrated through ELISA assays and flow cytometry. AptaTeck Bio's technology is suitable for detecting various target molecules, including biomarkers, viral and bacterial antigens, nucleic acids, and cell surface antigens, serving the pharmaceuticals sector.
Strategic signal
In January 2017, AptaTeck Bio presented its universal probe for signal amplification in antibodies and nucleic acid aptamers based immuno-diagnostic assays at the Isranalytica conference. This presentation highlighted the company's core technological innovation, signaling its potential to enhance the sensitivity and accuracy of diagnostic tools within the pharmaceutical and life sciences industries. For investors, this indicates a focus on foundational technology development with broad application potential in diagnostics.
Log in to access full profile ›Company Intelligence Q&A
- What is AptaTeck Bio's core technology?
- AptaTeck Bio has developed a proprietary technology based on an amplification probe for highly sensitive immuno-assays, employing both antibodies and aptamers.
- When was AptaTeck Bio founded?
- AptaTeck Bio was founded in January 2009.
- Who is a co-founder of AptaTeck Bio?
- Ofer Nussbaum is a co-founder and CTO of AptaTeck Bio.
- What platforms are compatible with AptaTeck Bio's system?
- AptaTeck Bio's system is compatible with various automated and manual platforms and can be integrated into most current commercial platforms, including ELISA assays and flow cytometry.
- What types of molecules can AptaTeck Bio's technology detect?
- AptaTeck Bio's technology is suitable for detecting a variety of target molecules, including biomarkers, viral and bacterial antigens, nucleic acids, cell surface, and soluble antigens.